Johnson & Johnson Initiates the Development of Vaccines Against Coronavirus

 Johnson & Johnson Initiates the Development of Vaccines Against Coronavirus

Johnson & Johnson Initiates the Development of Vaccines Against Coronavirus

Shots:

  • J&J launches a multi-pronged response to the Coronavirus (2019-nCoV or Wuhan coronavirus) outbreak and collaborating with others to screen a library of antiviral therapies
  • The vaccine program leverages Janssen’s AdVac and PER.C6 technologies, providing the ability to rapidly upscale production of the optimal vaccine therapy. The company utilize its same technology in its Ebola vaccine, currently being administered in the Democratic Republic of Congo and Rwanda
  • Additionally, Janssen has denoted 300 boxes of Prezcobix (darunavir/cobicistat) to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University to support efforts in finding a solution against the 2019-nCoV and 50 boxes to the Chinese Center for Disease Control and Prevention for laboratory-based investigations

Click here ­to­ read full press release/ article | Ref: Johnson & Johnson | Image: NYTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post